

Table of Contents

List of Abbreviations/Acronyms	xii
List of Symbols	xvi
List of Tables	xviii
List of figures.....	xxi
Preface	xxvi
Chapter 1: Neurodegenerative disorder: Alzheimer’s disease	1
1.1 Neurodegenerative disorders	1
1.1.1 Alzheimer’s disease	1
1.1.2 Parkinson’s disease	2
1.1.3 Amyotrophic lateral sclerosis	2
1.1.4 Huntington disease.....	2
1.1.5 Frontotemporal dementia.....	3
1.2 Pathophysiology of Alzheimer’s disease	3
1.2.1 Role of amyloid precursor protein	4
1.2.2 Role of beta-secretase	4
1.2.3 Role of amyloid beta.....	5
1.2.4 Role of monoamine oxidase	5
1.2.5 Role of tau-tubulin kinase.....	6
1.2.6 Role of tau.....	6
1.2.7 Acetylcholine	6
1.2.8 Role of glutamate.....	7
1.2.9 Role of N-methyl-D-aspartate receptor	7
1.2.10 Role of neuropeptides	8
1.2.11 Neuroprotective role of estrogens in Alzheimer’s disease	8
1.3 Stages of Alzheimer’s disease	9
1.3.1 Early stage.....	9
1.3.2 Middle stage.....	11
1.3.3 Late stage	11
1.4 Diagnosis of Alzheimer’s disease.....	12
1.4.1 Assessing memory problems and other symptoms.....	12
1.4.2 Laboratory tests.....	12

1.4.3 Brain-imaging tests	13
1.5 Treatment of Alzheimer's disease	13
1.5.1 Pharmacological treatment	13
1.5.2 Non-pharmacological therapy for AD	15
1.6 References.....	18
Chapter 2: Identification of matrix metalloproteinase-9 inhibitors	23
2.1 Introduction.....	23
2.2 Materials and Methods.....	25
2.2.1 Computational details	25
2.2.2 Energetically optimized structure-based pharmacophore generation	26
2.2.3 Enrichment calculations.....	29
2.2.4 Ligand-based pharmacophore generation	30
2.2.5 External validation of 3D-QSAR models	32
2.2.6 Database preparation.....	32
2.2.7 Pharmacophore-based screening of the database.....	33
2.2.8 Removal of pan-assay interference compounds	33
2.2.9 High-throughput virtual screening and molecular docking	33
2.2.10 Induced fit docking	34
2.2.11 Prime MM-GBSA simulation.....	35
2.2.12 Docking using AutoDock	36
2.2.13 Prediction of ADME.....	37
2.2.14 Density functional theory.....	37
2.2.15 <i>In silico</i> MMP-9 selectivity determination	38
2.2.16 <i>In vitro</i> MMP-9 enzyme inhibition.....	38
2.2.17 <i>In vitro</i> AChE and BuChE enzyme inhibition.....	39
2.2.18 Assay of propidium iodide displacement.....	40
2.2.19 <i>In vitro</i> blood-brain barrier permeation assay.....	41
2.2.20 Determination of cellular cytotoxicity and neuroprotection.....	42
2.2.21 Molecular dynamics simulation.....	43
2.3 Results and Discussion	45
2.3.1 Energetically optimized structure-based pharmacophore generation	45
2.3.2 Validation of e-pharmacophore model	47
2.3.3 Development of ligand-based pharmacophore model	49
2.3.4 Validation of 3D-QSAR models.....	51

2.3.5 Analysis of contour maps	53
2.3.6 Pharmacophore-based virtual screening, removal of PAINS and molecular docking.....	55
2.3.7 Induced fit docking	56
2.3.8 Determination of Prime MM-GBSA	58
2.3.9 AutoDock simulation.....	58
2.3.10 Prediction of ADME properties	58
2.3.11 Density functional theory.....	60
2.3.12 Determination of MMP-9 selectivity.....	61
2.3.13 <i>In vitro</i> MMP-9 enzyme inhibition.....	63
2.3.14 <i>In vitro</i> blood-brain barrier permeation assay.....	66
2.3.15 Cytotoxicity and neuroprotection assessment.....	67
2.3.16 Molecular dynamics simulation.....	69
2.4 Conclusions.....	70
2.5 References.....	73
Chapter 3: Discovery of PAS selective acetylcholinesterase inhibitors	83
3.1 Introduction.....	83
3.2 Materials and Methods.....	85
3.2.1 Computational details	85
3.2.2 Development of ligand-based pharmacophore	86
3.2.3 Validation of ligand-based pharmacophore	86
3.2.4 Energy-optimized structure-based pharmacophore generation	87
3.2.5 Energy-optimized structure-based pharmacophore validation	88
3.2.6 Pharmacophore-based screening of the database.....	89
3.2.7 Removal of pan-assay interference compounds	89
3.2.8 High throughput virtual screening and molecular docking	90
3.2.9 Induced fit docking	90
3.2.10 Docking using Autodock	91
3.2.11 Prime MM-GBSA simulation.....	92
3.2.12 ADME properties prediction	92
3.2.13 Density functional theory.....	93
3.2.14 <i>In silico</i> AChE selectivity study	93
3.2.15 <i>In vitro</i> AChE and BuChE enzyme inhibition.....	94
3.2.16 Assay of propidium iodide displacement.....	94

3.2.17 <i>In-vitro</i> blood-brain barrier permeation assay	94
3.2.18 Determination of cellular cytotoxicity and neuroprotection.....	94
3.2.19 Molecular dynamics simulation.....	94
3.3 Results and Discussion	95
3.3.1 Development of ligand-based pharmacophore model	95
3.3.2 Validation of ligand-based pharmacophore model	95
3.3.3 Development of energy-optimized structure-based pharmacophore	96
3.3.4 Validation of energy-optimized structure-based pharmacophore.....	100
3.3.5 Pharmacophore matched screening and removal of pan-assay interference compounds	100
3.3.6 High throughput virtual screening and molecular docking	101
3.3.7 Induced fit docking	105
3.3.8 Docking with AutoDock.....	105
3.3.9 Calculation of Prime MM-GBSA	105
3.3.10 Prediction of ADME properties	105
3.3.11 Density functional theory.....	108
3.3.12 <i>In silico</i> AChE selectivity study	109
3.3.13 <i>In vitro</i> inhibition of AChE and BuChE	110
3.3.14 Propidium iodide displacement assay.....	113
3.3.15 <i>In vitro</i> blood-brain barrier permeation assay.....	114
3.3.16 Cellular cytotoxicity and neuroprotection assessment.....	114
3.3.17 Molecular dynamics simulation.....	115
3.4 Conclusions.....	116
3.5 References.....	120
Chapter 4: Identification of human tau-tubulin kinase 1 inhibitors	125
4.1 Introduction.....	125
4.2 Materials and Methods.....	128
4.2.1 Details of computational work tools	128
4.2.2 Development of energy-optimized structure-based pharmacophore	128
4.2.3 Validation of energy-optimized structure-based pharmacophore.....	129
4.2.4 Pharmacophore-based screening of database	130
4.2.5 Removal of pan-assay interference compounds	130
4.2.6 High throughput virtual screening and molecular docking	130
4.2.7 Induced fit docking	131

4.2.8 ADME properties and blood-brain barrier permeability prediction	132
4.2.9 Molecular dynamics simulation.....	132
4.3 Results and Discussion	133
4.3.1 Development of energy-optimized structure-based pharmacophore	133
4.3.2 Validation of energy-optimized structure-based pharmacophore.....	133
4.3.3 High throughput virtual screening and molecular docking	136
4.3.4 Induced fit docking	137
4.3.5 Predicted ADME properties and blood-brain barrier permeability	144
4.3.6 Molecular dynamics simulation.....	145
4.4 Conclusions.....	146
4.5 References.....	148
Chapter 5: Synthesis and evaluation of multitargeted anti-Alzheimer's agent derived from 4-oxo-N, 4-diphenyl-butanamides and (E)-N-aryl-4-hydroxy-4-phenylbut-2- enamides	151
5.1 Introduction.....	151
5.2 Materials and Methods.....	153
5.2.1 Fragment-based drug design.....	153
5.2.2 Molecular docking	154
5.2.3 Determination of drug-likeness	154
5.2.4 Organic chemistry.....	155
5.2.5 Biological assays.....	176
5.2.6 Molecular dynamics simulation.....	178
5.3 Results and Discussion	179
5.3.1 Fragment based drug design	179
5.3.2 Molecular docking	181
5.3.3 Determination of drug-likeness	184
5.3.2 Organic synthesis.....	187
5.3.3 Biological assays.....	187
5.3.4 Molecular dynamics simulation.....	196
5.4 Conclusions.....	200
5.5 References.....	201
Chapter 6: Summary and Perspective	203
Appendix	207